Paul L Nguyen

University Of California, San Francisco

$1,913,227

Attributed

$4,027,780

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $815.7K · FY2020–25

$1M$750K$500K$250K$0

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$4,027,780 · 2

By mechanism

R01$4,027,780 · 2

Top collaborators

Most similar at University Of California, San Francisco

Same institution · by research overlap

Nola M. Hylton$19,153,972
Felix Yi-Chung Feng$6,764,664
Martin Edwin Gleave$1,721,828
Daniel B Vigneron$43,424,992
Susan Halabi$7,630,539

Others in their field

Other Emerging Leaders on “Phase Iii Trial”

Kimberly Smith · Ppd Development Lp$122,008,792
Yunda Huang · Fred Hutchinson Cancer Center$52,249,798
Susan Abushakra · Alzheon, Inc.$51,190,244
Timothy Fouts · Advanced Bioscience Laboratories, Inc.$45,097,399
Greg Yothers · University Of Chicago$25,122,895
Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108

Research focus

Phase Iii TrialProstate Cancer RiskNational Comprehensive Cancer NetworkPersonalized MedicinePredictive MarkerPrognostic MarkerHigh RiskMarkov ModelClinical TranslationCost EffectiveDiagnosisPredicting ResponsePrognosticBiological MarkersGenomicsGuidelinesClia CertifiedMalignant Neoplasm Of ProstateAndrogen Deprivation TherapyClinical PredictorsCancer PatientCostDecision AnalysisRadiation Therapy